Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.

Journal of translational medicine - 3 Feb 2021

Feng Weiwei, Jia Nan, Jiao Haining, Chen Jun, Chen Yan, Zhang Yueru, Zhu Menghan, Zhu Chongying, Shen Lifei, Long Wenqing

Abstract excerpt

BACKGROUND: Currently, there is no reliable blood-based marker to track tumor recurrence in endometrial cancer (EC) patients. Liquid biopsies, specifically, circulating tumor DNA (ctDNA) analysis emerged as a way to monitor tumor metastasis. The objective of this study was to examine the feasibility of ctDNA in recurrence surveillance and prognostic evaluation of high-risk EC. METHODS: Tumor tissues from nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to ARID1A gene

Share to TP53 gene

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33536036
DOI: 10.1186/s12967-021-02722-8
PMCID: PMC7860194

Genes

ARID1A
ATM
FAT4
PTEN
TP53
ZFHX3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.PMID 33536036Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancerSemantic proximity Read ↗

Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and ProgressionSemantic proximity Read ↗

Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.Semantic proximity Read ↗

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.Semantic proximity Read ↗

Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progressionSemantic proximity Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.Semantic proximity Read ↗

ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATIONSemantic proximity Read ↗

Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and PlasmaSemantic proximity Read ↗

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.Semantic proximity Read ↗

Sensitive Detection of Gynecological Cancer Recurrence Using Circulating Tumor DNA and Digital PCR: A Comparative Study with Serum Biochemical Markers.Semantic proximity Read ↗

Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.